$ARWR Covid Shined Light on Biotech, and Bulls See Even Brighter 2021 - Bloomberg https://www.bloomberg.com/news/articles/2020-12-15/covid-shined-light-on-biotech-and-bulls-see-even-brighter-2021
Covid Shined Light on Biotech, and Bulls See Even Brighter 2021

This year’s meteoric rise in biotech stocks is here to stay.

https://www.bloomberg.com/news/articles/2020-12-15/covid-shined-light-on-biotech-and-bulls-see-even-brighter-2021
RNA mentioned. $ARWR still flying under the radar when proper credit is awarded for pipeline depth. ~Of equal or more significance is the closely conjoined profit potential. Arrowhead has a clear and substantive lead moving (blockbuster patient populations) drugs to market 1st.
No coincidence whatsoever Goldman Sachs modest price target of $94.00 recognizes the increased likelihood of blockbuster approvals here. $ARWR
$ALNY success with small patient population indications is instrumental sector wide, but “disruptive” and valuation changing profit is $ARWR domain. Looking at future value comparatively & holistically it becomes much easier to see Arrowhead as a hidden gem in my humble opinion.
You can follow @truthtracer.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled:
Those who think consciousness raising & movement building are disconnected, or even a distraction from electoral politics have not paid attention to the history of social change.In this thread, we
Read more
The 2020s will be known as the Remote Work decadeA few predictions of what is likely to emerge[ a thread ] Third Space: Office and Working from Home will
Read more
1/29: Have you ever had a concept explained to you that helps frame complex issues you’ve been wrestling with and opens your eyes to new possibilities? A concept that I
Read more
By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.